Document Detail

Nateglinide (Starlix): update on a new antidiabetic agent.
MedLine Citation:
PMID:  12918894     Owner:  NLM     Status:  MEDLINE    
Nateglinide is a new oral antidiabetic agent that stimulates insulin release promptly after its pre-meal administration in a strongly glucose-dependent fashion. Because its insulinotropic effects are short in duration, nateglinide specifically targets postprandial hyperglycaemia with a low potential to elicit hypoglycaemia or sustained hyperinsulinaemia. Nateglinide has an excellent safety and tolerability profile, and its efficacy in reducing HbA1c in monotherapy (120 mg before meals) is comparable to that of metformin, sulphonylureas, thiazolidinediones or acarbose (-0.5 to -1.5%). When combined with metformin, which primarily reduces fasting glucose levels, nateglinide's effects are additive. In our clinical experience, nateglinide is a particularly good therapeutic option in newly diagnosed, treatment-naive patients; elderly patients in whom hypoglycaemia is a concern; patients with kidney failure or mild hepatic impairment; patients taking low-dose sulphonylureas who encounter problems with hypoglycaemia; and patients failing to achieve adequate glycaemic control on metformin or thiazolidinedione monotherapy.
L S Phillips; B E Dunning
Related Documents :
21623214 - Vitamin d status in patients with chronic obstructive pulmonary disease who participate...
15114274 - Gastric myoelectrical activity and intracranial hypertension.
21606454 - Vitamin d in african americans with multiple sclerosis.
25107604 - Associations between glycated albumin or hemoglobin a1c and the presence of coronary ar...
9298374 - Acute and chronic management of lower gastrointestinal bleeding: cost-effective approac...
1405364 - Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory?
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  International journal of clinical practice     Volume:  57     ISSN:  1368-5031     ISO Abbreviation:  Int. J. Clin. Pract.     Publication Date:    2003 Jul-Aug
Date Detail:
Created Date:  2003-08-15     Completed Date:  2003-10-01     Revised Date:  2007-02-14    
Medline Journal Info:
Nlm Unique ID:  9712381     Medline TA:  Int J Clin Pract     Country:  England    
Other Details:
Languages:  eng     Pagination:  535-41     Citation Subset:  IM    
Division of Endocrinology/Metabolism, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Glucose / physiology
Cyclohexanes / pharmacokinetics,  therapeutic use*
Diabetes Mellitus, Type 2 / complications,  drug therapy*
Hyperglycemia / complications,  drug therapy*
Hypoglycemic Agents / pharmacokinetics,  therapeutic use*
Phenylalanine / analogs & derivatives,  pharmacokinetics,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Blood Glucose; 0/Cyclohexanes; 0/Hypoglycemic Agents; 105816-04-4/nateglinide; 63-91-2/Phenylalanine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Xeloda and Taxotere: a review of the development of the combination for use in metastatic breast can...
Next Document:  Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy.